Fiche publication
Date publication
juillet 2016
Journal
Scientific reports
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROUX Stéphane
Tous les auteurs :
Dufort S, Le Duc G, Salomé M, Bentivegna V, Sancey L, Bräuer-Krisch E, Requardt H, Lux F, Coll JL, Perriat P, Roux S, Tillement O
Lien Pubmed
Résumé
We recently developed the synthesis of ultrasmall gadolinium-based nanoparticles (GBN), (hydrodynamic diameter <5 nm) characterized by a safe behavior after intravenous injection (renal clearance, preferential accumulation in tumors). Owing to the presence of gadolinium ions, GBN can be used as contrast agents for magnetic resonance imaging (MRI) and as radiosensitizers. The attempt to determine the most opportune delay between the intravenous injection of GBN and the irradiation showed that a very low content of radiosensitizing nanoparticles in the tumor area is sufficient (0.1 μg/g of particles, i.e. 15 ppb of gadolinium) for an important increase of the therapeutic effect of irradiation. Such a promising and unexpected result is assigned to a suited distribution of GBN within the tumor, as revealed by the X-ray fluorescence (XRF) maps.
Mots clés
Animals, Cell Line, Contrast Media, administration & dosage, Gadolinium, administration & dosage, Gliosarcoma, radiotherapy, Magnetic Resonance Imaging, methods, Male, Nanoparticles, administration & dosage, Radiation-Sensitizing Agents, administration & dosage, Rats, Rats, Inbred F344, X-Rays
Référence
Sci Rep. 2016 07 14;6:29678
